BEUDAMED
    14 results · 22ms · Sources: EU EUDAMED, US FDA

    Get notified when this changes

    We'll email you when new records match this search — new devices, new clearances, certificate changes, or withdrawals.
    Filters Regulation: Us FDA ×

    Argulated Locking Plates

    FDA 510(k)
    FDA Class 2 ·Dental

    E.M Adams co, inc.

    FDA UDI
    E.M. ADAMS, INC.·10840200301661·SINGLE INSTRUMENT

    E.M Adams co, inc.

    FDA UDI
    E.M. ADAMS, INC.·18100013401661·SINGLE INSTRUMENT

    BLAKSTONE LAMINOPLASTY FIXATION SYSTEM

    FDA 510(k)
    FDA Class 2 ·Orthopedic

    COOLTOUCH

    FDA 510(k)
    FDA Class 2 ·General, Plastic Surgery

    IDENTITY ADX XL DR

    FDA Adverse Event
    Malfunction ·ST. JUDE MEDICAL INC. CRMD·Product code DXY·January 13, 2014

    MICRO SAGITTAL SAW

    FDA Adverse Event
    Malfunction ·STRYKER INSTRUMENTS-KALAMAZOO·Product code HBE·June 3, 2013

    E. WALKER 6MM LT MED FOSSA

    FDA Adverse Event
    Injury ·BIOMET MICROFIXATION·Product code LZD·June 29, 2011

    TECNIS

    FDA Adverse Event
    Injury ·JOHNSON & JOHNSON SURGICAL VISION, INC.·Product code HQL·September 6, 2018

    CEPHALOMEDULLARY TARGETING GUIDE STANDARD

    FDA Adverse Event
    Malfunction ·ZIMMER BIOMET, INC.·Product code HSB·April 7, 2023

    ZNN¿¢, CMN LAG SCREW, ø 10.5 MM, 115 MM INCLUDING SET SCREW

    FDA Adverse Event
    Injury ·ZIMMER SWITZERLAND MANUFACTURING GMBH·Product code HSB·April 20, 2023

    5.0 MM DIAMETER CORTICAL SCREW - RED FIXED ANGLE 3.5 MM HEX HEAD

    FDA Adverse Event
    Malfunction ·ZIMMER BIOMET, INC.·Product code HSB·April 7, 2023

    5.0 MM DIAMETER CORTICAL SCREW - RED FIXED ANGLE 3.5 MM HEX HEAD

    FDA Adverse Event
    Malfunction ·ZIMMER BIOMET, INC.·Product code HSB·April 7, 2023

    BD FocalPoint Slide Profiler and BD FocalPoint GS Review Station; Catalog Nos. 490398, 490653, 491085, 491086, 491090, 490189 The BD FocalPoint GS Imaging System is intended to assist in cervical cancer screening of BD SurePath Liquid-based Pap Test slides to detect evidence of squamous carcinoma, adenocarcinoma and their usual precursor conditions.

    FDA Enforcement
    Class III ·Terminated·Becton Dickinson & Co.·October 17, 2018